Clinical Trials Logo

Critical Limb Ischemia clinical trials

View clinical trials related to Critical Limb Ischemia.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT03253328 Suspended - Diabetes Mellitus Clinical Trials

N-Acetyl-Cysteine (NAC) for Healing of Amputation Stumps in the Setting of Diabetes

Start date: December 15, 2016
Phase: N/A
Study type: Interventional

In this pilot clinical study the investigators propose to conduct a prospective, randomized, double-blinded, placebo-controlled clinical trial for 30 days for participants with critical limb ischemia (CLI) who undergo a major (above-knee or below-knee) lower extremity amputation. By exploring the primary endpoints we aim to determine whether NAC can affect amputation stump perfusion and healing. Based on preclinical data, the investigators hypothesize that NAC will augment both amputation stump perfusion as well as healing. The investigators will utilize the data from this trial to determine the true effect size that is necessary for a larger clinical trial to determine the clinical efficacy of NAC is healing surgical sites such as major lower extremity amputation stumps.

NCT ID: NCT03175744 Suspended - Clinical trials for Critical Limb Ischemia

Stellarex DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries

ILLUMENATE-BTK
Start date: May 24, 2017
Phase: N/A
Study type: Interventional

The purpose is to demonstrate the safety and effectiveness of the Stellarex DCB for the treatment of stenosis or occlusions of below-the-knee arteries.

NCT ID: NCT02140931 Suspended - Clinical trials for Critical Limb Ischemia

Assessment of Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia

Start date: August 2014
Phase: Phase 2
Study type: Interventional

A randomized, double-blind placebo controlled study to determine the safety and efficacy of Angiogenic Cell Precursors (ACPs) in relieving symptoms of Critical Limb Ischemia in patients treated with standard of care and with no surgical revascularization option. It is assumed that the ACP-treated group will have a lower amputation and death rate as compared to the placebo group. Other hemodynamic, imaging and clinical parameters will also be compared between the two groups. Quality of life assessments will also be performed.